---
document_datetime: 2023-09-21 18:42:01
document_pages: 39
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/ivabradine-zentiva-epar-public-assessment-report_en.pdf
document_name: ivabradine-zentiva-epar-public-assessment-report_en.pdf
version: success
processing_time: 21.313813
conversion_datetime: 2025-12-31 05:09:01.828302
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

15 September 2016 EMA/73167/2017 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Ivabradine Zentiva

International non-proprietary name: ivabradine

Procedure No. EMEA/H/C/004117/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................9                                 |                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................9      |                                                                                                      |
| 1.2. Steps taken for the assessment of the product.......................................................10                |                                                                                                      |
| 2. Scientific discussion ..............................................................................11                  |                                                                                                      |
| 2.1. Introduction.......................................................................................................11 |                                                                                                      |
| 2.2. Quality aspects                                                                                                       | ..................................................................................................12 |
| 2.2.1. Introduction....................................................................................................12  |                                                                                                      |
| 2.2.2. Active substance                                                                                                    | ............................................................................................13       |
| 2.2.3. Finished medicinal product................................................................................15        |                                                                                                      |
| 2.2.4. Discussion on chemical, and pharmaceutical aspects............................................18                    |                                                                                                      |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                  | ......................18                                                                             |
| 2.2.6. Recommendation for future quality development.................................................18                    |                                                                                                      |
| 2.3. Non-clinical aspects                                                                                                  | ............................................................................................18       |
| 2.3.1. Introduction....................................................................................................18  |                                                                                                      |
| 2.3.2. Ecotoxicity/environmental risk assessment                                                                           | .........................................................19                                          |
| 2.3.3. Conclusion on the non-clinical aspects................................................................19            |                                                                                                      |
| 2.4. Clinical aspects                                                                                                      | ..................................................................................................19 |
| 2.4.1. Introduction....................................................................................................19  |                                                                                                      |
| 2.4.2. Pharmacokinetics.............................................................................................20     |                                                                                                      |
| 2.4.3. Pharmacodynamics..........................................................................................25        |                                                                                                      |
| 2.4.4. Post marketing experience................................................................................25         |                                                                                                      |
| 2.4.5. Discussion on clinical aspects                                                                                      | ............................................................................25                       |
| 2.4.6. Conclusions on clinical aspects                                                                                     | ..........................................................................26                         |
| 2.5. Risk management plan........................................................................................27        |                                                                                                      |
| 2.6. PSUR submission................................................................................................36     |                                                                                                      |
| 2.7. Pharmacovigilance..............................................................................................36     |                                                                                                      |
| 2.8. Product information ............................................................................................36    |                                                                                                      |
| 2.8.1. User consultation.............................................................................................36    |                                                                                                      |
| 3. Benefit-risk balance                                                                                                    | ..............................................................................37                     |
| 4. Recommendation...................................................................................38                     |                                                                                                      |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADR

Adverse Drug Reaction

AE

adverse event

AESI

AEs of special interest

ALP

alkaline phosphatase

ALT

alanine aminotransferase

ANSM

National Agency for the Safety of Medicine and Health Products

AP

Applicant's Part of ASMF

API

Active Pharmaceutical Ingredient

APPM

Association of Paediatric Palliative Medicine Master Formulary

AR

Assessment Report

ASM

Active Substance Manufacturer

ASMF

Active Substance Master File = Drug Master File

AST

aspartate aminotransferase

AUC

Area Under the plasma Concentration

AUC0-inf

Area Under the plasma Concentration-time curve from time zero to infinity

AUC0-t

Area Under the plasma Concentration-time curve from time zero to t hours

BA

BioAvailability

BCT

Blinded combination therapy

BE

Bioequivalence

BID

bis in die (twice daily)

BMI

Body Mass Index

BPI

Brief Pain Inventory

BNFc

British National Formulary for Children

BUN

blood urea nitrogen

CI

confidence interval

CIOMS

Suspect Adverse Reaction Report Form

Cl

Clearance

CLcr

creatinine clearance

Cmax

maximum plasma concentration

CMH test

Cochran-Mantel-Haenszel test

CoA

Certificate of Analysis

CP

cerebral palsy

CPPs

Critical process parameters

CQAs

Control quality attributes

CRO

Certified Research Organisation

CSF

cerebrospinal fluid

CV

Coefficient ov Variation

CYP450

cytochrome P450

DAP

Drug Analysis Print

DDI

Drug-drug interactions

DHCP

Direct Healthcare Professional Communication

DMF

Drug Master File = Active Substance Master File

DoE

Design of experiments

DP

Decentralised (Application) Procedure

DP

Drug product

DS

Drug substance

DSC

Differential Scanning Calorimetry

EC

Europena Commission

ECG

Electrocardiogram

EEG

electroencephalogram

eGFR

estimated glomerular filtration rate

eGFRCKD-EPI eGFRMDRD

estimated glomerular filtration rate based on the Chronic Kidney Disease

Epidemiology Collaboration equation

estimated glomerular filtration rate based on the Modification of Diet in

<div style=\"page-break-after: always\"></div>

| ECHO              | echocardiography                                              |
|-------------------|---------------------------------------------------------------|
| EMA               | European Madicines Agency                                     |
| EoS               | End os Study                                                  |
| ERA               | endothelin receptor antagonist                                |
| ERT               | enzyme replacement therapy                                    |
| ESI               | Electro Spray Ionisation                                      |
| ETA               | endothelin receptor antagosinsts                              |
| EU                | European Union                                                |
| FAV               | Final Assessment Visit                                        |
| FEV1              | Forced expiratory volume in one second                        |
| FMEA              | Failure mode and effects analysis                             |
| FPM               | Finish Product Manufacturer                                   |
| FT-IR             | Fourier Transform Infrared Spectroscopy                       |
| GABA              | Gamma-aminobutyric acid                                       |
| GAD               | Generalised Anxiety Disorder                                  |
| GC                | Gas Chromatography                                            |
| GCP               | Good Clinical Practice                                        |
| GFR               | glomerular filtration rate                                    |
| GGT               | gamma-glutamyl transpeptidase                                 |
| GL-3              | globotriaosylceramide                                         |
| GLA               | gene encoding α-Gal A                                         |
| GLP               | Good Laboratory Practice                                      |
| GMP               | Good manufacturing practice                                   |
| GP                | Glycopyrronium                                                |
| GSRS              | Gastrointestinal Symptoms Rating Scale                        |
| Hb                | Haemoglobin                                                   |
| HCl               | hydrochloride                                                 |
| HCP HCT           | Health Care Professional hematocrit                           |
| HDPE              | High Density Polyethylene                                     |
| HEK               | human embryonic kidney                                        |
| HPLC              |                                                               |
|                   | High pressure liquid chromatography                           |
| HR                | Hazard Ratio                                                  |
| HRD               | human recommended dose Committee for Human Medicine Products  |
| CHMP IAR          | infusion-associated reaction                                  |
| IC                | interstitial capillary                                        |
| IC GL-3           | interstitial capillary GL-3                                   |
| ICD               | Informed Consent Document                                     |
| ICMR              | Indian council of medical research                            |
| ICSR              | Individual Case Safety Report                                 |
| IEC               | Independent Ethics Committee                                  |
| IgG               | immunoglobulin G                                              |
| ICH               | International Conference on Harmonisation                     |
| IMP               | Investigated Medicinal product                                |
| IMS               | International Marketing Sales                                 |
| INN               | International Non-proprietary Name                            |
| IP                | investigational product                                       |
| IPC IR            | In-process control Incidence Rate                             |
| IR                | Immediate-release or Infra-red                                |
| IRB               | Institutional Review Board                                    |
| ISR               | Incurred Sample Reanalysis                                    |
| IS-normalized ITT | Internal Standard-normalised Matrix Factor Intention To Treat |
|                   | Intravenous                                                   |
| IV                | Japanese                                                      |
| JP                | Pharmacopeia Japanese Pharmaceutical                          |
| JPE               | Excipients                                                    |
| K2EDTA            | dipotassium ethylenediaminetetraacetic acid                   |

K i

dissociation constant for binding of inhibitor to enzyme

<div style=\"page-break-after: always\"></div>

KF Karl Fischer titration LC-MS/MS

liquid chromatography coupled with tandem mass spectrometry

LDPE

LFT

Low density polyethylene

Liver Function tests

LLOQ

Lower Limit of Quantification

LOA

Letter of Access

LOD

LOD

Loss on drying

Limit of Detection

LOQ

(1) Limit of Quantification, (2) List of Questions

LV

left ventricular

LVEDP

Left ventricular end diastolic pressure

LVH

Left ventricular hypertrophy

LVMi

Left ventricular mass index

lyso-Gb3

globotriaosylsphingosine

MA

Marketing Authorisation

MAA

Marketing Authorization Application

MAH

Marketing Authorisation holder

mBMRS

modified Behavioural and Medical Rating Scale

M.D.

Medical Doctor

MDRD

Modification of Diet in Renal Disease equation

mGFR

measured glomerular filtration rate

mGFR iohexol

glomerular filtration rate as measured by plasma clearance of iohexol

mGFRiohexol

glomerular filtration rate measured by the plasma clearance of unlabelled iohexol

MHRA

Medicines and Healthcare Products Regulatory Agency

mITT

Modified Intended To Treat

mITT-amenable

patients with amenable mutations in the AT1001-011 mITT population

mPAP

Mean Pulmonary Artery Pressure

MR

Medical Representative

MRI

Magnetic resonance imaging

MS

Mass Spectrometry

mTDS

modified 9-point Teacher's Drooling Scale

MWD

minute walk distance

NAION

Non-Arteritic Anterior Ischemic Optic Neuropathy

NCA

National Competent Authority

ND

Not detected

NHS

National Health Service

NMR

Nuclear Magnetic Resonance

NMT

Not more than

NSAID

Non-Steroidal Anti-Inflammatory Drug

NYHA

New York Heart Association

OECD

Organisation for Economic Co-operation and Development

OLE

open-label  extension

OOS

OPA

Oriented polyamide

film

Out of Specifications

OTC

Over-the-counter

PAH

Pulmonary Arterial Hypertension

PBMC

peripheral blood mononuclear cell

PCA

prescription cost analysis data

PCD

Photo-Contact Dermatitis

PCTFE

Polychlorotrifluoroethene

PCWP

pulmonary capillary wedge pressure

PD

pharmacodynamics

PDE

Permitted Daily Exposure

PDE-5

phosphodiesterase type-5

PE

Polyethylene

PEC

Predicted Enviromental Concentration

P-gp

P-glycoprotein

Ph.Eur.

European Pharmacopoeia

PhV

Pharmacovigilance

PIL

Patient Information Leaflet

PIP

Paediatric Investigational Plan

PK

pharmacokinetic

PMS

Post Marketing Surveillance

PP

Polypropylene

PRO

Patient-Reported Outcome

PS

Photo-Sensitivity

PSMF

Pharmacovigilance Systém Master File

PSUR

Periodic Safety Update Report

PT

Preferred Term

PTH

Pituitary thyroid hormone

PUMA

Paediatric Use Marketing Authorisation

PVC

Poly vinyl chloride

PVDC

Polyvinylidene chloride

PVOD

Pulmonary Veno-Occlusive Disease

PVR

Pulmonary vascular resistance

QA

Quality Assurance

QbD

Quality by design

QC

Quality Control (samples)

QD

quaque die (once daily)

QOD

every other day

QOD

quaque otra die (once every other day)

QOS

Quality Overall Summary

QP

Qualified Person

QTc

QT interval corrected for heart rate

QTPP

Quality target product profile

Rf

Retention factor

RH

Relative Humidity

rhα-Gal A

recombinant human α-Gal A

RMM

Risk Minimization Measure

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| RMS                      | Reference Member State                                |
|--------------------------|-------------------------------------------------------|
| RR                       | Reporting Rate                                        |
| RRT                      | Relative retention time                               |
| RSD                      | Relative standard deviation                           |
| Rt                       | Retention time                                        |
| SAE                      | serious adverse event                                 |
| SAO2                     | oxygen saturation                                     |
| SEM                      | standard error of the mean                            |
| SF-36v2                  | Short Form Health Survey with 36 questions, version 2 |
| SGLT1                    | sodium glucose cotransporter 1                        |
| SGOT                     | Serum glutamic oxaloacetic trnasaminase               |
| SGPT                     | Serum glutamic pyruvic trnasmainase                   |
| Shire HGT                | Shire human genetic therapies                         |
| SME                      | small, or medium-sized enterprise                     |
| SmPC                     | Summary of Product Characteristics                    |
| SMQ                      | Standardised MedDRA Querie                            |
| SOC                      | System Organ Class                                    |
| SOP                      | Standard Operating Procedure                          |
| SPC                      | Summary of Product Characteristics                    |
| STD                      | Standard Deviation                                    |
| T/R                      | Test/Reference                                        |
| t 1/2                    | terminal elimination half-life                        |
| TEAE                     | treatment-emergent adverse event                      |
| THF Tétrahydrofurane TID | tris in die (three times a day)                       |
| TLC                      | Total lung capacity                                   |
| t max                    | time to maximum plasma concentration                  |
| tmax                     | time of occurrence of Cmax                            |
| TSE                      | Transmissible spongiform encephalopathy               |
| TTC                      | Threshold of toxicological concern                    |
| ULN                      | upper limit of normal                                 |
| USP                      | United States pharmacopoeial                          |
| UV                       | Ultraviolet                                           |
| VAS                      | visual analogue scale                                 |
| Vss                      | volume of distribution                                |
| WBC                      | white blood cell                                      |
| WCI                      | Worst Case Imputation                                 |
| WEU                      | Well Established Use                                  |
| WHO                      | World Health Organization                             |
| WRI                      | worst rank imputation                                 |
| WT                       | wild type                                             |
| XRD                      | X-Ray Diffraction                                     |
| XRPD                     | X-ray powder diffraction                              |
| α-Gal A                  | alpha-galactosidase A                                 |
| μCi                      | Microcurie                                            |

<div style=\"page-break-after: always\"></div>

μM Micromolar

Not all abbreviations might be used.

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Zentiva, k.s. submitted on 4 November 2015 an application for marketing authorisation to the European Medicines Agency (EMA) for Ivabradine Zentiva, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004- 'Generic of a Centrally authorised product. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 20 November 2014.

The application concerns a generic medicinal product as defined in Article 10(2)(b) of Directive 2001/83/EC and refers to a reference product for which a marketing authorisation is or has been granted in the Union on the basis of a complete dossier in accordance with Article 8(3) of Directive 2001/83/EC.

The applicant applied for the following indications:

Symptomatic treatment of chronic stable angina pectoris

Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated:

- in adults unable to tolerate or with a contra-indication to the use of β-blockers or

- in combination with β-blockers in patients inadequately controlled with an optimal β-blocker dose.

## Treatment of chronic heart failure

Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including βblocker therapy or when β-blocker therapy is contraindicated or not tolerated (see section 5.1).

## The legal basis for this application refers to:

Generic application (Article 10(1) of Directive No 2001/83/EC).

The application submitted is composed of administrative information, complete quality data and a bioequivalence study with the reference medicinal product Procoralan instead of non-clinical and clinical unless justified otherwise.

## Information on paediatric requirement

Not applicable

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

The chosen reference product is:

Medicinal product which is or has been authorised in accordance with Community provisions in force for not less than 6/10 years in the EEA:

- Product name, strength, pharmaceutical form: Procoralan 5 mg, 7.5 mg film-coated tablets
- Marketing authorisation holder: Les Laboratoires Servier, France
- Date of authorisation: 25-10-2005
- Marketing authorisation granted by:
- -Community
- Community Marketing authorisation number: EU/1/05/316/001-007, EU/1/05/316/008-014

Medicinal product authorised in the Community/Members State where the application is made or European reference medicinal product:

- Product name, strength, pharmaceutical form: : Procoralan 5 mg, 7.5 mg film-coated tablets
- Marketing authorisation holder: Les Laboratoires Servier, France
- Date of authorisation: 25-10-2005
- Marketing authorisation granted by:
- -Community
- Community Marketing authorisation number: EU/1/05/316/001-007, EU/1/05/316/008-014

Medicinal product which is or has been authorised in accordance with Community provisions in force and to which bioequivalence has been demonstrated by appropriate bioavailability studies:

- Product name, strength, pharmaceutical form: Procoralan 7.5 mg film-coated tablets
- Marketing authorisation holder: Les Laboratoires Servier, France
- Date of authorisation: 25-10-2005
- Marketing authorisation granted by:
- -Community
- Community Marketing authorisation number: EU/1/05/316/012
- Bioavailability study number(s): 2014-3595 (IVABRL07375)

## Scientific advice

The applicant did not seek scientific advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP was:

Rapporteur: Radka Montoniová

- The application was received by the EMA on 4 November 2015.
- The procedure started on 4 December 2015.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 19 February 2016. The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on 3 March 2016

<div style=\"page-break-after: always\"></div>

- During the meeting on 1 April 2016, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 01 April 2016
- The applicant submitted the responses to the CHMP consolidated List of Questions on 20 May 2016.
- The Rapporteur circulated the Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 27 June 2016
- During the PRAC meeting on 8 July 2016, the PRAC agreed on a PRAC Assessment Overview and Advice to CHMP.

During the CHMP meeting on 21 July 2016 , the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant

- The applicant submitted the responses to the CHMP consolidated List of Outstanding Issues on 01 September 2016..
- During the meeting on 15 September 2016, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing authorisation to Ivabradine Zentiva.

## 2. Scientific discussion

## 2.1. Introduction

The  proposed  product  is  an  immediate  release  film-coated  5mg  and  7,5  mg  tablets  containing ivabradine hydrochloride as active substance. Ivabradine hydrochloride is a chemical substance and the dosage form has been developed as generic product to the centrally authorised product Procorolan 7,5 mg film-coated tablets containing the same active substance in the same pharmaceutical form.

Ivabradine is an anti-anginal and anti-ischaemic agent, which selectively and specifically inhibits the I f current  in  the  sino-atrial  node  and  provides  heart  rate  reduction  without  altering  other  cardiac parameters, including conduction, and without directly affecting other haemodynamic parameters. The positive effect of ivabradine on angina pectoris symptoms and its ability to reduce myocardial ischemia make  it  an  important  agent  in  the  management  of  patients  with  stable  CAD  or  chronic  HF  as documented by current clinical practice guidelines [Ponikowski et al. 2016; Montalescot et al. 2013; NICE 2011].

The generic medicinal product has applied for all the indications of the reference medicinal product. The indications applied and approved by the CHMP are:

## Symptomatic treatment of chronic stable angina pectoris

Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated:

- -in adults unable to tolerate or with a contra-indication to the use of β-blockers

or

- -in combination with β-blockers in patients inadequately controlled with an optimal β-blocker dose.

<div style=\"page-break-after: always\"></div>

## Treatment of chronic heart failure

Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including βblocker therapy or when β-blocker therapy is contraindicated or not tolerated.

The recommended dose range is from 2.5 to 7.5 mg twice daily.

## Symptomatic treatment of chronic stable angina pectoris

The starting dose of ivabradine should not exceed 5 mg twice daily in patients aged below 75 years. After three to four weeks of treatment, if patient is still symptomatic, the dose may be increased to the next higher dose in patients receiving 2.5 mg twice daily or 5 mg twice daily. The maintenance dose should  not  exceed  7.5  mg  twice  daily.  If  there  is  no  improvement  in  symptoms  of  angina  within  3 months after start of treatment, treatment of ivabradine should be discontinued. Treatment must be discontinued  if  heart  rate  remains  below  50  bpm  or  symptoms  of  bradycardia  persist  despite  dose reduction.

## Treatment of chronic heart failure

The usual recommended starting dose of ivabradine is 5 mg twice daily. After 2 weeks of treatment, the dose can be increased to 7.5 mg twice daily if resting heart rate is persistently above 60 bpm or decreased to 2.5 mg twice daily (one half 5 mg tablet twice daily) if resting heart rate is persistently below 50 bpm or in case of symptoms related to bradycardia such as dizziness, fatigue or hypotension. If heart rate is between 50 and 60 bpm, the dose of 5 mg twice daily should be maintained. If during treatment,  heart  rate  decreases  persistently  below  50  bpm  at  rest  or the  patient  experiences symptoms  related  to  bradycardia,  the  dose  must  be  titrated  downward  to  the  next  lower  dose in patients  receiving  7.5  mg  twice  daily  or  5  mg  twice  daily.  If  heart  rate  increases  persistently above 60 bpm at rest, the dose can be up titrated to the next upper dose in patients receiving 2.5 mg twice daily or 5 mg twice daily. Treatment must be discontinued if heart rate remains below 50 bpm or symptoms of bradycardia persist.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as film-coated tablets containing 5 or 7.5 mg ivabradine (as hydrochloride) as active substance. The 5 mg tablet can be divided into equal doses.

## Other ingredients are:

For the tablet core: mannitol, crospovidone, magnesium stearate.

For the film coating: hypromellose, titanium dioxide, macrogol 400, glycerol.

The product is available in OPA/Alu/PVC-Alu blisters as described in section 6.5 of the SmPC.

<div style=\"page-break-after: always\"></div>

## 2.2.2. Active  substance

## General information

The chemical name of ivabradine hydrochloride is 3-(3-{[((7S)-3,4-Dimethoxybicyclo[4.2.0]octa1,3,5-trien-7-yl)methyl] methyl amino} propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2one, hydrochloride corresponding to the molecular formula C27H36N2O5.HCl. It has a relative molecular mass of 505.05 g/mol and the following structure:

<!-- image -->

The active substance is a white to slightly yellow hygroscopic powder, soluble in water and methanol, practically insoluble in THF.

The active substance exhibits stereoisomerism due to the presence of one chiral centre. The desired isomer is the S-form. The R-isomer is controlled routinely as an impurity in the active substance by a stereo-selective analytical method.

Polymorphism has been observed for the active substance. A list of 29 polymorphic forms, mentioned in the literature, has been presented together with their XRD patterns, DSC information and for some of them also manufacturing process. The active substance manufacturer consistently manufactures the same polymorphic form. Undesired conversion of crystalline form was observed in stability (refer to 'Stability'). Further based on the investigations that were carried out, appropriate control strategy was put in place to prevent undesired change in the polymorph during active substance manufacture and stability. Polymorphic form of the active substance is also controlled in the active substance specifications.

## Manufacture, characterisation and process controls

Detailed information on the manufacturing of the active substance has been provided in the restricted part of the ASMF and it was considered satisfactory.

The active substance is synthesized by one manufacturer in eleven main steps using well defined starting materials with acceptable specifications. The originally proposed starting materials were re defined during the procedure at the request of CHMP to ensure that enough of the process is conducted under GMP. The chiral centre is generated during the process. The synthetic strategy and process design such as reagent selection, process parameters and in-process controls ensure the desired configuration at the chiral centre.

Reprocessing of active substance is described and considered acceptable.

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products and reagents have been presented.

The structure of the active substance has been confirmed by the following methods:  1 H- and  13 C- NMR, FT-IR, mass spectra, XRPD, elemental analysis and specific optical rotation. The characterisation of the

<div style=\"page-break-after: always\"></div>

active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances.

Potential and actual impurities were well discussed with regards to their origin and characterised. Genotoxic impurities were investigated and appropriate control strategy was put in place.

The active substance is packaged appropriately.

## Specification

The active substance specification includes tests and limits for the following parameters: appearance (Ph. Eur.), solubility (Ph. Eur.), identity (IR, chloride test Ph. Eur.), assay (HPLC), related substances (HPLC), R-isomer (HPLC), genotoxic impurity (HPLC), 1 bromo-3-chloro propane (GC), residual solvents (GC), water content (KF), heavy metals (Ph. Eur.),  sulphated ash (Ph. Eur.), chloride content (potentiometric titration), specific optical rotation (Ph. Eur.), polymorphism (XRD) and particle size (laser diffraction).

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines.  Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis data are provided for three production scale batches of the active substance. The results are within the specifications and consistent from batch to batch.

## Stability

Stability data were provided on three production scale batches of active substance manufactured by the proposed manufacturer according to the proposed process and stored in a container closure system representative of that intended for the market for 9 months under long term conditions at 25 ºC / 60% RH and intermediate conditions at 30 ºC / 65% RH and for up to 6 months under accelerated conditions at 40 ºC / 75% RH according to the ICH guidelines. Stability data were also provided on three production scale batches of active substance manufactured by the proposed manufacturer according to the initial process and stored for 24 months under long term conditions at 25 ºC / 60% RH and for 6 months under accelerated conditions at 40 ºC / 75% RH according to the ICH guidelines.

The following parameters were tested : appearance, water content, R-isomer, assay, related substances, genotoxic impurity Benzocyclobutane and polymorphism. The analytical methods used were the same as for release and were stability indicating.

An out of specification results for polymorphism was observed for one of the three supportive stability batches (initial process). In view of this failure, the stability studies were reinitiated. During investigation it was also decided to improve packaging step. The results of the re-initiated stability studies indicated that the active substance batches (initial process) are complying with the stability specification including test for polymorphism at 6 months accelerated and 18 months long-term stability station. However at 24 months long-term stability two of the three batches did not comply with the test for polymorphism by XRD.

Further, the first three production scale batches of ivabradine hydrochloride active substance manufactured by making minor changes in the manufacturing process were also kept for stability studies. Out of the three batches, one batch did not comply with the test for polymorphism at 3 months accelerated stability. An appropriate control strategy was put in place with regard to

<div style=\"page-break-after: always\"></div>

preventing the undesired change in the polymorph. The retest period and storage precaution was also reconsidered in accordance with the stability results. Furthermore as both polymorphs observed are hydrates, they also have similar characteristics and there is no change in the quality of the finished product. Moreover it has been confirmed that only the expected form is presented in the finished product (refer to 'Stability of the product').

Forced  degradation  studies  including  photostability  studies  according  to  the  ICH  Q1B  have  been provided. No decrease was observed for assay with exception of treatment with acid heat and oxidative heat  treatment.  As  for  related  substances  method,  no  significant  degradation  as  observed  with exception of acid heat treatment and oxidative heat treatment.  The substance has been shown to be stable under light conditions.

The stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period of 18 months with the storage condition 'store below 25 ºC' in the proposed container.

## 2.2.3. Finished medicinal product

## Description of the product and Pharmaceutical development

The finished product comes as oblong, one side and both edges scored white film coated tablet 5 mg and white to off white, round film coated tablet 7.5 mg.

The aim was to develop a stable and robust formulation, bioequivalent to the reference product Procoralan. All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur standards with the exception of the film coating, although it is composed of a mixture of compendial components. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.1.1 of this report. The formulation of the test product differs from that of the reference product. The reference product contains lactose monohydrate, maize starch, maltodextrin, silica (colloidal anhydrous) and magnesium stearate and the tablet core is coated with an aqueous film coat which consists of hypromellose, titanium dioxide, macrogol 6000, glycerol, magnesium stearate, yellow iron oxide and red iron oxide. For the proposed finished product the compatibility of the active substance with the excipients was based on stability studies. A detailed account of the development of the formulation was presented with clear explanations provided for the changes made at each point. The role, the choice of the excipients and their concentration has been satisfactorily justified.

Direct compression is used to manufacture the finished product. The manufacturing process consists of blending, compression and coating step. Manufacturing process optimisation was described. The overage used during the coating process was satisfactorily justified.

The proposed finished products Ivabradine 5 mg film coated tablet and Ivabradine 7.5 mg film coated tablet are manufactured by the same manufacturing process, the composition is qualitatively the same and quantitatively proportional.

Influence of tablet hardness was investigated. It was observed that tablet hardness increase does not have a significant effect on dissolution. Influence of active substance particle size distribution on

<div style=\"page-break-after: always\"></div>

dissolution was investigated. The results confirmed the limit choice for the active substance specifications.

Data demonstrating the absence of polymorphic form change during the manufacturing process of the proposed finished product were provided. Possible change of the active substance polymorphic form during storage was studied. Polymorphism of the reference product was also investigated. Several polymorphic forms were observed depending on the batch. Different reference product batches and proposed finished product batches were investigated for similarity of dissolution profiles at different media (pH 1, pH 4.5, pH 6.8). Based on the results it was concluded that different polymorphic forms have no effect on dissolution profile and bioequivalence of products. It was observed that polymorphic structure was not critical for finished product quality.

Ivabradine 5 mg film coated tablet contains break-mark. Three finished product batches were tested according to Ph. Eur. breakability test. Results comply with Ph. Eur. requirements. Content uniformity of half tablet was also investigated on one batch. Results complied with requirements. Dissolution profile of half tablet was also evaluated with release media to show similarity. Dissolution profiles of Ivabradine 5 mg film coated tablet, Ivabradine 5 mg film coated half tablet and Ivabradine 7.5 mg film coated tablet were evaluated at pH 1. Profiles were found similar. The compliance of subdivision of tablet was demonstrated sufficiently.

A bioequivalence study was performed with the 7.5 mg strength showing bioequivalence between of the proposed finished product and the reference medicinal product. The formulation used for the bioequivalence study is the same as that intended for marketing. Based on the comparison of dissolution profiles of Ivabradine 7.5 mg film coated tablet and Procoralan 7.5 mg film coated tablet, where for both products more than 85 % of active substance is dissolved in 15 minutes in pH 1, pH 4.5 and pH 6.8, it was concluded that dissolution profiles are similar. A biowaiver was requested for the 5 mg strength based on the result from BE-study with 7.5 mg strength. Dissolution profiles of Ivabradine 7.5 mg and 5 mg film coated tablet were compared and it was observed that they are similar in pH 1, pH 4.5 and pH 6.8. All the conditions for biowaiver for additional product strengths as stated in the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98) are fulfilled; therefore the bioequivalence results of the 7.5 mg strength can be extended to the 5 mg strength.

The development of the dissolution method is described and the discriminatory power has been demonstrated with regard to the amount of applied film coating and minimal changes in the tablet composition.

The impurity profiles of both generic and reference products in all strengths are similar.

The primary packaging is OPA/Alu/PVC-Alu blisters. The material complies with EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

The manufacturing process consists of five main steps: sieving, blending, compression, film coating and packaging. The process is considered to be a standard manufacturing process.

Major steps of the manufacturing process have been validated by a number of studies on three pilot scale batches of each strength. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls

<div style=\"page-break-after: always\"></div>

are adequate for this type of manufacturing process and pharmaceutical form. Adequate justification for holding times of bulk intermediates (coating solution, tablet cores, and film-coated tablets prior to packaging) has been provided.

Validation will be performed post-approval on the first three consecutive production scale batches of each strength as per a protocol, which has been presented and is considered acceptable.

## Product specification

The finished product specifications include appropriate tests for this kind of dosage form: appearance (visual examination), identification (HPLC, UV, TiO2 test), average film coated tablet weight (Ph.Eur.), subdivision of tablets (Ph. Eur.), LOD (Ph.Eur.), disintegration (Ph.Eur.), assay (HPLC), uniformity of dosage  units-content uniformity (Ph.Eur.), dissolution, impurities  (HPLC),  microorganism  count (Ph.Eur.) and polymorphism (XRD).

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis results were provided for three production scale batches of each strength confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

## Stability of the product

Stability data were provided for three pilot scale batches of finished product of 5 mg strength stored under long term conditions for 18 months at 25 ºC / 60% RH, under intermediate conditions for 12 months at 30 ºC / 65% RH and for 18 months at 30 ºC / 75% RH, and for up to 6 months under accelerated conditions at 40 ºC / 75% RH according to the ICH guidelines.

Stability data were provided for three pilot scale batches of finished product of 7.5 mg strength stored under long term conditions for up 18 months at 25 ºC / 60% RH, under intermediate conditions for 12 months at 30 ºC / 75% RH and for up to 18 months at 30 ºC / 75% RH, and for up to 6 months under accelerated conditions at 40 ºC / 75% RH according to the ICH guidelines.

The batches of medicinal product are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing.

Samples were tested according to the shelf-life specifications described in the previous section. The analytical procedures used are stability indicating.

Out of specifications results were observed for the polymorphic form of two batches at 6 months at 40 °C/75 % RH and for three batches at 12 months at 30 °C/75 % RH. The results for polymorphism are in line with specification criteria in long term stability condition (25 °C ± 2 °C/60 ± 5 % RH). For the 7.5 mg strength, 18 months stability data is available only for one batch (12 month is available for the other two batches). Since the formulation of 7.5 mg and 5 mg tablets are proportional, based on available stability results it is expected that the stability of the 7.5 mg strength will not differ from the stability of the 5 mg strength. These finding dictated the product shelf life and storage conditions.

In addition, one batch of 7.5 mg strength was tested under daylight at 25 ºC / 60% RH according to ICH Q1B Guideline (directly exposed product, product in primary package and complete package

<div style=\"page-break-after: always\"></div>

product). Parameters tested were: appearance, assay, dissolution, impurities and polymorphism. Based on the results the finished product is not light sensitive.

Based on available stability data, the proposed shelf-life of 18 months with the following storage precautions: 'Store below 25 °C' and 'Store in the original package in order to protect from moisture.' as stated in the SmPC (section 6.3) are acceptable.

## Adventitious agents

No excipients derived from animal or human origin have been used.

## 2.2.4. Discussion on chemical, and pharmaceutical aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. Polymorphism has been observed for the active substance. The active substance manufacturer consistently manufactures the same polymorphic form (crystalline form II which is also a hydrated form).  Undesired conversion of crystalline form II to form γ was observed in stability of the active substance and finished product. Further based on the investigations that were carried out, it was understood that the water content and storage conditions have an impact on the polymorph. Hence appropriate control strategy was put in place to prevent undesired change in the polymorph during active substance and finished product manufacture and stability. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.6. Recommendation for future quality development

None.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date and adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, pharmacokinetics and toxicology data.

<div style=\"page-break-after: always\"></div>

Pharmacodynamic, pharmacokinetic and toxicological properties of ivabradine are well known.  As ivabradine is a widely used, well-known active substance, no further studies are required. Overview based on literature review is, thus appropriate. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. The impurity profile has been discussed and was considered acceptable.

Therefore, the CHMP agreed that no further non-clinical studies are required.

## 2.3.2. Ecotoxicity/environmental risk assessment

The Environmental Risk Assessment was submitted according to the EMA Guideline on Environmental Risk  Assessment  of  Medicinal  Products  for  Human  Use  (EMEA/CHMP/SWP/4447/00  corr  21*) .  Since Ivabradine Zentiva is intended for generic substitution, this should not lead to an increased exposure to  the  environment.  Also  the  PECsurfacewater was  calculated  to  be  0.0003  µg/l  (total  EU  worst  case scenario),  which  is  acceptable.  Since  the  PECsurfacewater  was  calculated  to  be  below  0.01  µg/l  and considering the fact, that ERA is not deemed necessary for products which are intended as a substitute for other identical products on the market, the approach of the applicant was considered acceptable. As  per EMA  Guideline  on  Environmental  Risk  Assessment  of  Medicinal  Products  for  Human  Use (EMEA/CHMP/SWP/4447/00 corr 21*) if the PECSURFACEWATER value is below 0.01 μg/L(3), and no other environmental concerns are apparent, it is assumed that the medicinal product is unlikely to represent a risk for the environment following its prescribed usage in patients.

## 2.3.3. Conclusion on the non-clinical aspects

A summary of the literature with regard to non-clinical data of Ivabradine Zentiva was provided and was accepted by the CHMP. This is in accordance with the relevant guideline and additional non clinical studies were not considered necessary.

## 2.4. Clinical aspects

## 2.4.1. Introduction

This is an application for film-coated tablets containing ivabradine hydrochloride. To support the marketing authorisation application the applicant conducted one bioequivalence study with cross-over design under fed conditions. This study was the pivotal study for the assessment.

The applicant provided a clinical overview outlining the pharmacokinetics and pharmacodynamics as well as efficacy and safety of ivabradine hydrochloride based on published literature. The SmPC is in line with the SmPC of the reference product.

No CHMP scientific advice pertinent to the clinical development was given for this medicinal product.

For the clinical assessment the EMA Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **) as well as the EMA Guideline on Bioanalytical method validation (EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2**) in their current version, are of particular relevance.

<div style=\"page-break-after: always\"></div>

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

According to the statement in the study report, the BE study was performed as per the protocol and in compliance with the requirements of current GCP, and in particular with the requirements of ICH Guideline for Good Clinical Practice, according to the principles of GCP having their origin in the Declaration of Helsinki, ethical requirements of Article 8.3 (i b) of Directive 2001/83/EC and ethical requirements of Directive 2001/20/EC.

## Exemption

The applicant applied for marketing authorization for two different strengths of ivabradine containing film-coated tablets: 5 mg and 7.5 mg. Bioequivalence was demonstrated for the highest strength (i.e. 7.5 mg). In vivo bioequivalence study waiver was sought for the lower strength of 5 mg based on the consideration of the general biowaiver criteria as specified in the EMA Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **).

Drug  products  Ivabradine  5  mg  film  coated  tablet  and  Ivabradine  7.5  mg  film  coated  tablet  are manufactured  by  the  same  manufacturing  process,  the  composition  is  qualitatively  the  same  and quantitatively proportional. Dissolution profiles of Ivabradine 5 mg film coated tablet and Ivabradine 7.5 mg film coated tablet are similar in all dissolution media.

## Clinical studies

To support the application, the company has submitted one bioequivalence study No. IVABRL07375 - a single-dose, open-label, single-center, randomized, two-period, two-treatment, two-sequence, crossover comparative bioavailability study conducted in forty healthy volunteers under fed conditions.

Table 1. Tabular overview of clinical studies

<!-- image -->

## 2.4.2. Pharmacokinetics

Study IVABRL07375: A single-dose, open-label, single-center, randomized, two-period, twotreatment, two-sequence, crossover comparative bioavailability study of two formulations of Ivabradine 7.5mg film-coated tablets conducted under fed conditions.

Sponsor of the Study:

Zentiva, k.s., Czech Republic

<div style=\"page-break-after: always\"></div>

## Methods

## Study design

This  was  a  single-dose,  open-label,  single-center,  randomized,  two-period,  two-treatment,  twosequence, crossover comparative bioavailability study conducted in forty healthy volunteers under fed conditions.

After  an  overnight  fast  of  at  least  10  hours,  subjects  consumed  a  high-fat,  high-calorie  breakfast. Approximately half of the breakfast was consumed starting 15 minutes prior to drug administration. The other half was consumed within 30 minutes of starting the first half of the breakfast, after the administration of assigned drug product.

A  single  7.5  mg  dose  (one  tablet)  of  the  assigned  drug  product  was  administered  according  to  the randomization  scheme  with  240  mL  (±5  mL)  of  room  temperature  water.  Subjects  consumed  the entire 240 mL (±5 mL) of water during the drug administration process.

The washout period between drug administrations for each subject was at least 7 days.

The blood pressure and pulse rate were measured prior to drug administration and at 3 and 7 hours post-dose. The temperature of each subject was measured daily during confinement.

<div style=\"page-break-after: always\"></div>

## Test and reference products

| Product Characteristics                                    | Test product                                                                                                                                                                                                                                                                                                                                                   | Reference Product                                                         |
|------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Name                                                       | Ivabradine 7.5 mg, film coated tablet                                                                                                                                                                                                                                                                                                                          | Procoralan 7.5 mg, film coated tablet                                     |
| Strength                                                   | 7.5 mg                                                                                                                                                                                                                                                                                                                                                         | 7.5 mg                                                                    |
| Dosage form                                                | Film Coated Tablets                                                                                                                                                                                                                                                                                                                                            | Film Coated Tablets                                                       |
| Marketing Authorization Holder                             |                                                                                                                                                                                                                                                                                                                                                                | Les Laboratoires Servier 50,rue Carnot 92284 Suresnes cedex - France      |
| Manufacturer                                               | Zentiva, k.s. U kabelovny 130 10237 Praha 10 Czech Republic (Responsibility: secondary packaging, labelling, testing, storage,release and distribution to CRO) Zentiva Saglik Urunleri San ve Tic. A.S. Kucukkaristiran mah. Merkez sok.No:223/A,39780, Buyukkaristiran/Luleburgaz Kirklareli Turkey (Responsibility: fabrication, primary packaging, testing, | Servier (Ireland) Industries Ltd Gorey Road Arklow - Co.Wicklow - Ireland |
| Batch number                                               | P03032015                                                                                                                                                                                                                                                                                                                                                      | 197167                                                                    |
| Batch size (Biobatch)                                      | 100 000 FCT                                                                                                                                                                                                                                                                                                                                                    |                                                                           |
| Measured content(s) (% of label claim)                     | 101.24%                                                                                                                                                                                                                                                                                                                                                        | 99.13%                                                                    |
| CommercialBatchSize                                        | 100 000 - 1 000 000 FCT                                                                                                                                                                                                                                                                                                                                        |                                                                           |
| Expiry date (Retest date)                                  | 16.09.2015                                                                                                                                                                                                                                                                                                                                                     | 09/2017                                                                   |
| Location of Certificate of Analysis                        | Appendix 16.1.6                                                                                                                                                                                                                                                                                                                                                | Appendix 16.1.6                                                           |
| Member State where thereference product is purchased from: |                                                                                                                                                                                                                                                                                                                                                                | Germany                                                                   |
| This product was used in the following trials:             | 2014-3595 (Zentiva study number IVABRL07375)                                                                                                                                                                                                                                                                                                                   | 2014-3595 (Zentiva study number IVABRL07375)                              |

1 List for each active substance for fixed combinations

Ivabradine Zentiva 7.5mg film-coated tablet manufactured by Zentiva, k.s. has been compared to Procoralan 7.5mg film-coated tablet manufactured by Servier Industries Ltd.

<div style=\"page-break-after: always\"></div>

## Population studied

Forty (40) male and female, healthy, non-smoker subjects with a mean body mass index 25.6 kg/m 2 (range  18.5  -  29.3),  and  mean  age  39  years  (range:  18-54)  who  voluntarily  signed  the  informed consent were included in the study. Thirty-nine (39) subjects finished both periods that were included into pharmacokinetic dataset.

Dropouts - subject No. 8 was dropped due to positive urine test for tricyclic antidepressants, prior to Period 2.

Protocol deviations - one subject came late (9 minutes) to the clinical facility on the check-in day prior Period 2.

Concomitant medication - subject 25 took two 200 mg tablets of ibuprofen on 11 May 2015 (96 hours after dosing).

## Analytical methods

Ivabradine was determined by achiral HPLC method using tandem mass spectrometry detection (PMRI1492-14  v.00).  Ivabradine  and  internal  standard  (Rac-ivabradine-d6)  were  extracted  from  K2EDTA plasma by protein precipitation extraction. Plasma samples were precipitated with a mixture of organic solvents  and  supernatant  was  diluted  and  transferred  for  LC-MS/MS  analysis.  Fully  automated extraction can be also performed by the Hamilton Star Lab Automated System. The calibration range was from 0.100 to 100 ng/mL using a plasma sample volume of 0.100 mL.

Certificates  of  analysis  for  ivabradine  hydrochloride  and  Rac-ivabradine-d6  were  attached  to  the Analytical  report.  The  calibration  standards  and  QC  samples  were  prepared  from  different  stock solutions.

A  minimum  of  sixteen  (16)  QC  samples  (four  at  each  concentration  level)  were  included  in  each analytical  batch.  Samples  were  analysed  in  9  analytical  batches  each  of  them  containing  blank  and zero  samples,  nine  calibration  standards,  four  sets  of  QC  samples  at  four  levels  and  samples  from mostly  6  subjects.  To  ensure  that  there  is  no  carryover  between  injections,  blank  samples  were monitored. There was one minor protocol deviation with no impact on the study outcome.

## Bioanalytical method validation

The  validation  results  of  a  high  performance  liquid  chromatographic  method  using  tandem  mass spectrometry  detection  for  determination  of  ivabradine  in  human  plasma  were  presented  in  the Validation Report. The method was validated at Pharma Medica Research Inc., Bioanalytical Division in June  2014.  The  long  term  stability  data  of  ivabradine  in  solutions  and  in  human  plasma  were submitted. Certificates of analysis for ivabradine hydrochloride and Rac-ivabradine-d6 were attached to the  Validation  report.  Ivabradine  undergoes  extensive  metabolism.  The  major  metabolic  pathways include O-demethylation, N-demethylation and dehydrogenation. Under experimental conditions these metabolites will not reverse back to ivabradine.

## Pharmacokinetic variables

The following PK parameters were estimated for ivabradine using a non-compartmental approach in SAS (version 9.3): AUCt, AUCinf, Cmax, Tmax, Kel, T1/2. These are adequate and in line with the EMA Guideline on the investigation of bioequivalence ( CPMP/EWP/QWP/1401/98 Rev. 1/ Corr ** ) .

<div style=\"page-break-after: always\"></div>

## Statistical methods

## Randomization

Subjects were randomly assigned to one treatment sequence according to a predetermined computergenerated randomization scheme (procedure PLAN in SAS ® ).

## Blinding

This was an open-label study. Blinding was not applicable.

## Determination of Sample Size

Sample size was estimated to be 36 subjects. Four (4) extra subjects were included into the study to account for potential dropouts. Therefore, 40 subjects were enrolled into this study.

## Statistical Analysis

Descriptive statistics for the PK parameters of ivabradine were presented. The PROC GLM procedure from SAS version 9.3 was used.

Analysis  of  variance  (ANOVA)  was  performed  on  log-transformed  AUCt  and  Cmax  parameters.  The significance of the sequence, period treatment and subject (sequence) effects (all fixed) was tested.

Based  on the log-transformed parameters, the following criteria were used to evaluate the bioequivalence between the test and reference products: The 90% CIs of the relative mean AUCt and Cmax of the test to reference products should be between 80.00 and 125.00%.

Results

| Pharmacokinetic                                                                  | Test                                                                             | Test                                                                             | Reference                                                                        | Reference                                                                        |
|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| parameter                                                                        | arithmetic mean                                                                  | SD                                                                               | arithmetic mean                                                                  | SD                                                                               |
| AUC (0-t) (ng-h/mL)                                                              | 108.24                                                                           | 58.63                                                                            | 106.37                                                                           | 52.97                                                                            |
| C max (ng/mL)                                                                    | 34.68                                                                            | 15.21                                                                            | 30.80                                                                            | 13.28                                                                            |
| T max * (h)                                                                      | 1.00 (0.25 - 3.50)                                                               |                                                                                  | 1.25 (0.50 - 2.67)                                                               |                                                                                  |
| AUC 0-t area under the plasma concentration-time curve from time zero to t hours | AUC 0-t area under the plasma concentration-time curve from time zero to t hours | AUC 0-t area under the plasma concentration-time curve from time zero to t hours | AUC 0-t area under the plasma concentration-time curve from time zero to t hours | AUC 0-t area under the plasma concentration-time curve from time zero to t hours |

## Table 1: Summary of Study Results Based on Plasma Ivabradine Levels

## Table 2: Statistical analysis for Ivabradine (ln-transformed values)

| Pharmacokinetic parameter                  | Geometric Mean Ratio Test/Reference        | Confidence Intervals                       | CV%*                                       |
|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| AUC (0-t) (ng-h/mL)                        | 99.72%                                     | (94.52%, 105.21%)                          | 14.08                                      |
| C max (ng/mL)                              | 112.73%                                    | (103.02%, 123.35%)                         | 23.89                                      |
| * estimated from the Residual Mean Squares | * estimated from the Residual Mean Squares | * estimated from the Residual Mean Squares | * estimated from the Residual Mean Squares |

<div style=\"page-break-after: always\"></div>

## Safety data

There were totally 22 adverse events involving 15 subjects. All adverse events were judged to be mild in  severity.  Subject  25  experienced  vomiting  (96  hours  after  dosing).  This  adverse  event  was  not considered to be associated with the drug treatment and subject 25 did not withdraw from the study. Following  adverse  events  were  reported:  sleepiness  (6),  dizziness  (3),  catheter  site  reaction  (2), bradycardia (2), vomiting (1), cut on right side of forehead (1), chills (1), muscle fatigue (1), ringing in ear (1), chest discomfort (1), hypertension (1), runny nose (1), sinus congestion (1).

## Conclusions

Based on the presented bioequivalence study, Ivabradine Zentiva, 7,5 mg film-coated tablet was considered bioequivalent with Procoralan 7,5 mg film-coated tablet.

## 2.4.3. Pharmacodynamics

No new pharmacodynamic studies were presented and no such studies were required for this application.

## 2.4.4. Post marketing experience

No post-marketing data are available. The medicinal product has not been marketed in any country.

## 2.4.5. Discussion on clinical aspects

To support this application, the company has submitted one bioequivalence study and review of preclinical and clinical data. In this application, an essential similarity was claimed to the original medicinal product Procoralan, which was also used as reference product in bioequivalence study.

Submitted  bioequivalence  study  was  a  single-dose,  randomized,  crossover,  study  comparing  two formulations  of  ivabradine  7.5  mg  film-coated  tablets  under  fed  conditions.  The  study  has  been declared  to  be  conducted  in  GCP  setting,  and  list  of  GCP  inspections  of  individual  sites  have  been submitted.

To submit one bioequivalence study was considered acceptable since the application concerns an oral immediate release formulation (film-coated tablets) and the kinetics of ivabradine is linear over and oral dose range of 0.5 - 24 mg. The reference medicinal product is recommended to be taken during a meal; therefore bioequivalence study under fed conditions is optimal to demonstrate bioequivalence between test and reference medicinal products. Considering expected time to peak concentration (1 2 hours after administration) sufficient number of blood samples was taken to identify the Cmax. The plasma elimination half-life of ivabradine is 2 hours hence the sampling time of 12 hours is considered sufficient. This is further supported by the fact, that in no individual subject the extrapolated AUC was higher than 20%. The washout period of 7 days is appropriate. The inclusion and exclusion criteria are considered  acceptable.  Food,  alcohol,  herbal/natural  products,  nutritional  supplements,  caffeine  and xanthine  containing products, grapefruit products  and  other  medication  restrictions were  also adequate.      The  reason  for  drop-out  is  in  line  with  the  protocol  and  is  considered  acceptable.

<div style=\"page-break-after: always\"></div>

Concomitant medication (2 tablets of ibuprofen 200 mg), taken 96 hours after dosing, could not affect results  of  the  study  as  the  dosing  period  was  only  12  hours.  The  pharmacokinetic  variables  were adequate and in line with the EMA Guideline on bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr **) . Statistical methods are acceptable according to EMA Guideline on bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr **) . The 90% confidence interval for the ration of the Test and Reference products fell into the acceptance range of 80.00 - 125.00% both for AUC0-t and Cmax. No pre-dose concentrations were detected. One subject reached Tmax at the first sampling point. Since this issue  occurred  only  in  one  case  it  is  deemed  that  it  should  have  not  affected  the  study  validity. Sequence and period effect were not significant. The test and reference products had a comparable safety profile in terms of the nature of events and overall proportion of subjects who experienced AEs. No unexpected AEs have been observed.

The applicant has also requested biowaiver for 5 mg strength. Drug products Ivabradine 5 mg filmcoated tablet and Ivabradine 7.5 mg film-coated tablet are manufactured by the same manufacturing process,  the  composition  is  qualitative  same  and  quantitatively  proportional.  Dissolution  profiles  of Ivabradine  5  mg  film-  coated  tablet  and  Ivabradine  7.5  mg  film-coated  tablet  are  similar  in  all dissolution media. Regarding the linear kinetics of ivabradine in proposed strengths, the biowaiver is acceptable.

Based  on  the  presented  bioequivalence  study,  Ivabradine  Zentiva,  7,5  mg  film-coated  tablet  is considered bioequivalent with Procoralan, 7,5 mg film-coated tablet.

## 2.4.6. Conclusions on clinical aspects

A summary of the literature with regard to clinical data of Ivabradine was provided and was accepted by the CHMP. In addition, to support this application, the company has submitted one bioequivalence study. Based on the presented bioequivalence study, Ivabradine 7,5 mg film-coated tablet manufactured by Zentiva, k.s., Czech Republic, was considered bioequivalent with Procoralan 7,5 mg film-coated tablet. The applicant has also requested biowaiver for 5 mg strength and this was accepted by the CHMP. This is in accordance with the relevant guideline and additional clinical studies were not considered necessary.

<div style=\"page-break-after: always\"></div>

## 2.5. Risk management plan

## Safety concerns

<!-- image -->

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                       |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Atrial fibrillation Phosphenes / blurred vision Bradycardia Blood pressure increase in hypertensive patients 2nd and 3rd degree AVB ECG QT interval prolonged                                                                                                    |
| Important potential risks    | Supraventricular tachyarhythmias (SVT) other than atrial fibrillation Immune system disorders Severe ventricular arrhythmia Myocardial infarction                                                                                                                |
| Missing information          | Use in children and adolescent (below 18 years old) Use in pregnant and lactating women Use in  patients  with severe hepatic insufficiency Use in patients with severe renal impairment Chronic heart failure patients with intraventricular conduction defects |

## Pharmacovigilance plan

Not applicable

<div style=\"page-break-after: always\"></div>

Risk minimisation measures

| Safety concern      | Routineriskminimisationmeasures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Additional risk minimisationmeasures   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| Atrial fibrillation | Proposed text in SmPC Contraindications(AV-block of 3rd degree, sino-atrial block, pacemaker dependent, sick sinus syndrome, resting heart rate below 7o bpm prior to treatment) are reported in section 4.3. Warning in section 4.4 that: Ivabradine is not effective in the treatment or prevention of cardiac arrhythmias and therefore not recommended patients with atrial fibrillation. In patients treated with ivabradine the risk of developing atrial fibrillation is increased. Patients should be informed of signs and symptoms of atrial fibrillationandbeadvisedto contact their physician if these occur. Adviceinsection4.4toconsider the possibility of non-urgent DC- cardioversion24hoursafterthelast dose of ivabradine. Atrial fibrillation listed as common side effect amongst the cardiac disorders in section 4.8. Incidence of atrial fibrillation in clinical | None proposed                          |

<div style=\"page-break-after: always\"></div>

| Safety concern             | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Additional risk minimisation measures   |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
|                            | studies is reported in section 4.8. Prescription only medicine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                         |
| Phosphenes /blurred vision | Proposed text in SmPC Section4.7informsabout impaired driving ability due to visual symptoms have been reported. Ivabradine may cause transient luminous phenomena consisting mainly of phosphenes. Precaution when using machines or diving veichles should be taken. Explanation in section 4.8 that the most common adverse reactions with ivabradine, luminous phenomena (phosphenes) and bradycardia, are dose dependent and related to the pharmacological effect of the medicinal product. Luminous phenomena (phosphenes) listed as very common side effect amongst the eye disorders and duly described in section 4.8. Blurred vision listed as common side effect amongst the eye disorders in section 4.8. The pharmacodynamic mechanism through  which ivabradine causes phosphenes is reported in section 5.1. | None proposed                           |
| Bradycardia                | Prescription only medicine Proposed text in SmPC Recommended doses are fepoited in section 4.2. Warming to adjust treatment posology even suspending therapy in case patient experiences symptoms related to bradycardia. Precautions for patients with low heart ratearedescribedinsection4.4. Statement in section 4.4 that there is no evidence ofriskof(excessive)                                                                                                                                                                                                                                                                                                                                                                                                                                                       | None proposed                           |

<div style=\"page-break-after: always\"></div>

| Safety concern                                   | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Additional risk minimisation measures   |
|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
|                                                  | bradycardia on retuun to sinus rhythm when pharmacological cardioversion is initiated  inpatients  treated  with ivabradine. Phamacodynamic and Pharmacokinetic interactions potentially increasing the risk of anrhythmia and bradycardia are described in section 4.5. Explanation in section 4.8 that the most common adverse reactions related to ivabradine, luminous phenomena (phosphenes) and bradycardia, are dose dependent and related to the pharmacological effect of the medicinal product. Bradycardia listed as common side effect amongst the nervous system disorders. Expalnation that overdose may lead to severe and prolonged bradycardia and the way to treat the latter are provided in section 4.9. Statement in section 5.1 that the main pharmacodynamic property of ivabradine in humans is a specific dose dependent reduction in heart rate. Percentage ofpeople reporting bradycardia as adverse event during one study is reported in Clinical efficacy and |                                         |
| Blood pressure increase in hypertensive patients | Prescription only medicine Proposed text in SmPC Waming in section 4.4 that during a clinical study some transient episodes of imcreased 1bloodpressureoccurred shortly after blood pressure treatment was modified.The percentage of patients that experienced these episodes washigher inpeople treated with                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | None proposed                           |

<div style=\"page-break-after: always\"></div>

| Safety concern            | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Additional risk minimisation measures   |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
|                           | ivabradine than in people treated with placebo. Thus when treatment modifications are made in chronic heart failure patients treated with ivabradine blood pressure should be monitored at an appropriate interval. Uncontrolled blood pressure listed as common adverse reaction amongst vascular disorders in section 4.8. Prescription only medicine                                                                                                                                                                                                                    |                                         |
| 2nd and 3rd degree AVB    | Proposed text in SmPC AV-block of 3rddegreelistedas contraindication in section 4.3. Waming in section 4.4 that ivabradine is not recommended in patients with AV- block of 2nd degree. AV 2\"d and 3d degree block listed as veryrare adverse feactionamongst cardiac disorders in section 4.8.                                                                                                                                                                                                                                                                            | None proposed                           |
| ECG QT interval prolonged | Prescription only medicine Proposed text in SmPC Waming in section 4.4 that the use of ivabradine in patients with congenital QTsyndrome or treatedwith QT prolonging medicinal products should be avoided. Heart rate reduction, as caused by ivabradine, may exacerbate QT prolongation. QT prolonging medicinal products are listed in section 4.5. The concomitant use of these products with ivabradine should be avoided since QT prolongation may be exacerbated by heart rate reduction. If the combination appears necessary. close cardiac monitoring is needed. | None proposed                           |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                         | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Additional risk minimisation measures   |
|------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
|                                                                        | ECG prolonged QT interval listed as uncommon adverse feaction amongst investigations in section 4.8. Prescription only medicine                                                                                                                                                                                                                                                                                                                                                                                                                |                                         |
| Supraventricular tachyarrhythmias (SVT) other than atrial fibrillation | Proposed text in SmPC Waming in section 4.4 that ivabradine is not effective in the treatment or prevention of cardiac arrhythmias and likely losesitsefficacywhena tachyarrhythmia occurs (e.g. ventricular o1 supraventricular tachycardia). Ivabradine is therefore 101 recommended in patients with atrial fibrillation or other cardiac arrhythmias that interfere with sinus node function. Supraventricular extrasystoles listed as uncommon adverse feaction amongst cardiac disorder in section 4.8.                                  | None proposed                           |
| Immune system disorders                                                | Prescription only medicine Proposed text in SmPC Eosinophilia listed as common adverse reaction amongst blood and lymphatic system disorders in section 4.8.                                                                                                                                                                                                                                                                                                                                                                                   | None proposed                           |
| Severe ventricular arrhythmia                                          | Prescription only medicine Proposed text in SmPC Waming in section 4.4 that ivabradine is not effective in the treatment or prevention of cardiac arrhythmias and likely loses itsefficacywhen a tachyamhythmia occurs (e.g. ventricular o1 supraventricular tachycardia). Ivabradine is therefore 101 recommended in patients with atrial fibrillation or other cardiac arrhythmias that interfere with sinus node fimction. Chronic heart failure patients with intraventricular conduction defects (bumdle branch block left, bumdle branch | None proposed                           |

<div style=\"page-break-after: always\"></div>

| Safety concern                                      | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Additional risk minimisationmeasures   |
|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
|                                                     | block right) and ventricular dyssynchronyshouldbe monitored closely. Ventricular extrasystoles listed as common adverse reaction amongst cardiac disorder in section 4.8. Prescription only medicine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                        |
| Myocardial infarction                               | Proposed text in SmPC Acute myocardial infarction listed as contraindication in section 4.3. Waming in section 4.4 that ivabradine is indicated only for symptomatic treatment of chronic stable angina pectoris because ivabradine has no benefits on cardiovascular outcomes (e.g. myocardial infarction or cardiovascular death).                                                                                                                                                                                                                                                                                                                                                                       | None proposed                          |
| Use in children and adolescent (below 18 years old) | Proposed text in SmPC Section 4.2 states that the safety and efficacy of ivabradine for the treatment of chronic heart failure in children aged below 18 years have not yet been established. Result from clinical studies in pediatric patients are shown in section 5.1. The long-term effects of ivabradine on growth, puberty and general development as well as the long- term efficacy of therapy with ivabradine in childhood to reduce cardiovascular morbidity and mortality have not been studied. As written in section 5.2the pharmacokinetic profile of ivabradine in paediatric chronic heart failure patients aged 6 months to less than 18 years is similar to the one described in adults | None proposed                          |

<div style=\"page-break-after: always\"></div>

| Safety concern                                   | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Additional minimisation measures   | risk   |
|--------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|--------|
|                                                  | when a titration scheme based on age and weight is applied. Same similarity between paediatric and adult population has beenobservedfor the PK/PD relationship. Prescription only medicine                                                                                                                                                                                                                                                                                                                                                           |                                    |        |
| Use in pregnant and lactating women              | Proposed text in SmPC Section 4.3 informs that ivabradine is contraindicated in pregnancy. lactation and women of child-bearing potential not using appropriatecontraceptive measures. As stated in section 4.6 there are no or limited amount of data from the use of ivabradine in1 pregnant women. Therefore, ivabradine is contraindicated during pregnancy. Animal studies indicate that ivabradine excreted in milk.  Therefore, 1S ivabradine is contraindicated  during breast-feeding. Preclinical safety data are reported in section 5.3. | None proposed                      |        |
| Use in patients with severe hepatic msufficiency | Proposed text in SmPC Posology for patients with hepatic impairment is described in section 4.2. Severe hepatic insufficiency is listed amongst contraindications in section 4.3. As shown in section 5.2 in patients with mild hepatic impairment umbound AUC ofivabradine andthe main active metabolite were about 20% higher than in subjects with normal hepatic finction. No data are available in patients with severe hepatic impairment.                                                                                                     | None proposed                      |        |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                          | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                            | Additional risk minimisation measures   |
|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
|                                                                         | Prescription only medicine                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                         |
| Use in patients with severe renal impairment                            | Proposed text in SmPC As stated in section 4.2 no data are available in patients with creatinine clearance below 15 mL/min. Ivabradine should therefore be used with precaution in this population. Section 5.2 informs that the impact of renal impairment (creatinine clearance 15 60mL/min)on ivabradine pharmacokinetic is minimal, in relation with the low contribution of renal clearance (about 20%)to total elimination for both ivabradine and its main metabolite. | None proposed                           |
| Chronic heart failure patients with intraventricular conduction defects | Proposed text in SmPC Section 4.1 informs about approved use of ivabradine for the treatment of chronic heart failure. Warning in section 4.4 that chronic heart failure patients with intraventricular conduction defects (bundle branch block left, bundle branch block right) and ventricular dyssynchrony should be monitored closely. Prescription only medicine                                                                                                         | None proposed                           |

## Conclusion

The CHMP and PRAC considered that the risk management plan version 1.2 is acceptable.

The Drug Utilisation Study (DUS) imposed on the reference medicinal product compares the characteristics of new users and the patterns of use of ivabradine before and after implementation of the risk-minimisation measures (Q1 2010-Q4 2013 vs Q2v 2015-Q1 2016). This comparison cannot be made for generic products since they were not available before implementation of the risk minimisation measures. Results from the DUS of innovator will become available in Q2 2017. Since the SmPC for the generic ivabradine products will be fully aligned with the SmPC of the reference product, the future results from DUS were considered applicable to the generic product as well. Consequently, at this time there is no need to perform separate studies.

It was considered that the obligation imposed for the reference medicinal product should not be

<div style=\"page-break-after: always\"></div>

imposed on Ivabradine Zentiva. In the absence of any conditions imposed on Ivabradine Zentiva, it was concluded that this product should not be included in the list of products subject to additional monitoring under the mandatory or optional scope criteria and will not display the black triangle in the SmPC and PL.

## 2.6. PSUR submission

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.7. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8. Product information

## 2.8.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the EMA Guideline on the readability of the label and package leaflet of medicinal products for human use .

<div style=\"page-break-after: always\"></div>

## 3. Benefit-risk balance

This application concerns a generic version of ivabradine hydrochloride film-coated tablet. The reference product Procoralan is indicated for symptomatic stable angina pectoris in adult patients whose heart rate is over or equal 70 beats per minute in adult patients who do not tolerate or cannot take heart medicines called beta-blockers or in combination with beta-blockers in patients whose condition is not fully controlled with a betablocker and in chronic heart failure in adult patients whose heart rate is over or equal to 75 beats per minute. It is used in combination with standard therapy, including beta-blocker therapy or when beta-blockers are contraindicated or not tolerated.

No nonclinical studies have been provided for this application but an adequate summary of the available nonclinical information for the active substance was presented and considered sufficient. From a clinical perspective, this application does not contain new data on the pharmacokinetics and pharmacodynamics as well as the efficacy and safety of the active substance; the applicant's clinical overview on these clinical aspects based on information from published literature was considered sufficient.

The bioequivalence study forms the pivotal basis with the following design: a single-dose, open-label, single-centre, randomized, two-period, two-treatment, two-sequence, crossover comparative bioavailability study conducted in forty healthy volunteers under fed conditions. The study design was considered adequate to evaluate the bioequivalence of this formulation and was in line with the respective European requirements. Study in fed status was considered acceptable as per requirements in the SmPC of the reference medicinal product. Dose, sampling points, overall sampling time as well as wash-out period were adequate. The analytical method was validated. Pharmacokinetic and statistical methods applied were adequate.

The test formulation of Ivabradine 7.5mg film-coated tablets manufactured by Zentiva, k.s., met the protocol-defined criteria for bioequivalence when compared with the Procoralan 7.5 mg film-coated tablets. The point estimates and their 90% confidence intervals for the parameters AUC0-t,, and Cmax were all contained within the protocol-defined acceptance range of [range, e.g. 80.00 to 125.00%]. Bioequivalence of the two formulations was demonstrated.

A benefit/risk ratio comparable to the reference product can therefore be concluded.

The CHMP, having considered the data submitted in the application and available on the chosen reference medicinal product, is of the opinion that no additional risk minimisation activities are required beyond those included in the product information.

<div style=\"page-break-after: always\"></div>

## 4. Recommendation

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Ivabradine Zentiva is favourable in the following indication:

## Symptomatic treatment of chronic stable angina pectoris

Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 beats per minute (bpm). Ivabradine is indicated:

- -in adults unable to tolerate or with a contraindication to the use of β-blockers

or

- -in combination with β-blockers in patients inadequately controlled with an optimal β-blocker dose.

## Treatment of chronic heart failure

Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including βblocker therapy or when β-blocker therapy is contraindicated or not tolerated (see section 5.1).

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

<div style=\"page-break-after: always\"></div>

Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States.

Not applicable.